Clinical Trial Update: Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase I study SHR-1316 combined with carboplatin and etoposide as first-line treatment for extensive-stage small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• SHR-1316

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: Widespread Small Cell Lung Cancer | Phase 1 | Status: RECRUITING